Clinical Toxicology Regulatory Report Drafting
Draft CTD Module 2.3 safety narratives from toxicology data and adverse events
What You Can Do
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
Features
Consolidates adverse event data from parallel clinical trials into unified safety profiles with trend analysis
Transforms preclinical toxicology + limited human PK/PD into compliant 15-50 page safety sections
Year-over-year adverse event summaries with causality assessment and signal detection
Links receptor binding, metabolite data, and tissue distribution to clinical AE patterns
Rapid drafting of urgent safety communications for serious emerging signals
Structures vital signs, laboratory trends, and histopathology findings per CTD guidelines
Phase transition safety overviews (Phase 1→2, 2→3) with population-level risk stratification
Organizes clinical findings with mechanistic rationale for independent assessment committees
Example Output
Example 1: IND Safety Module Summary
Input: Phase 1 PK data (n=24), Phase 1b efficacy signals (n=12), preclinical GLP tox studies (28-day rat, 90-day dog), emerging QTc signal in 3 subjects.
Output:
Safety Summary – Section 2.3.5
Nonclinical Safety: 28-day rat study (GLP) at doses up to 100 mg/kg revealed no organ toxicity. 90-day dog study showed reversible hepatocyte hypertrophy at ≥50 mg/kg, not observed at 10 mg/kg. No genotoxicity in AMES or micronucleus.
Clinical Safety: 36 subjects across Phase 1/1b. Most common AE: headache (n=8, 22%), nausea (n=6, 17%), Grade 1-2. One Grade 2 QTc prolongation (475 ms) in subject receiving 400 mg; resolved upon dose reduction. No deaths, SAEs, or withdrawals due to safety.
Example 2: Annual Safety Update
Input: 12-month ongoing Phase 2b trial data (n=187), cumulative AE database, MedDRA coding, causality assessments.
Output:
Annual Safety Update – Year 1
AE Incidence: Overall AE rate 68% (127/187), consistent with year 1 baseline (69%). No new safety signals detected. GI AEs (n=34, 18%) remain most common, unchanged from pre-specified monitoring threshold. Serious AEs: 3 hospitalizations (pneumonia, appendicitis—unrelated; 1 Grade 3 drug-related rash).
Trend Analysis: QTc signal from IND phase resolved; mean QTc change from baseline –2 ms (95% CI: –8 to +4 ms).
What's Included
- SKILL.md instruction file: Complete toxicology report drafting workflow with regulatory templates
- IND Module 2.3 template: Pre-formatted sections for safety summary, detailed safety assessment, and laboratory summaries
- Annual Safety Update framework: Year-over-year trend analysis checklist with MedDRA coding guidelines
- Adverse Event synthesis checklist: Causality assessment, signal detection, and safety population definitions
- CTD compliance reference: Section numbering, regulatory language standards, and FDA/EMA formatting requirements
Who It's For
- Clinical toxicologists — Synthesizing safety data across preclinical and clinical programs
- Medical safety writers — Drafting regulatory-compliant safety narratives for submissions
- Regulatory affairs specialists — Assembling CTD modules and managing submission timelines
- Clinical development managers — Coordinating safety data for IND, ASR, and expedited reports
- Pharmacovigilance leads — Analyzing adverse event trends and preparing safety communications
Best For
- IND application safety modules — Initial comprehensive safety assessment for new drug investigations
- CTD Module 2.3 sections — Pre-approval dossier safety summaries and detailed assessments
- Annual Safety Update reports (ASR) — Year-over-year adverse event synthesis and trend analysis
- Expedited Safety Reports (ESR) — Rapid urgent safety communications for emerging signals
- Cross-trial safety meta-analysis — Clinical Development Safety Overviews for Phase transitions (2→3)
You might also like
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-w
You can architect end-to-end bioinformatics analysis pipelines by translating your research question into algorithmic approaches, selecting and optimizing appropriate tools and parameters for your dataset, and validating results against biological expectations. This skill guides you through the complete decision tree from raw data to publication-ready interpretation, helping you avoid parameter overfitting, misinterpreted statistical thresholds, and algorithm selection errors that compromise research validity.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
This skill helps you synthesize complex environmental toxicology and fate data into cohesive, regulatory-quality Environmental Assessment narratives. You can organize hazard identification, exposure assessment, and risk characterization frameworks; integrate multi-study ecotoxicity evidence; cross-reference FDA/EMA/ICH M7 guidance; and identify data gaps—all while maintaining scientific rigor and compliance consistency required for NDAs, INDs, and BPCIs.
by kody-w
Conduct comprehensive job risk assessments in minutes, generate detailed task analysis reports with biomechanical findings, and develop prioritized ergonomic interventions backed by OSHA and NIOSH guidelines. You'll identify risk factors, quantify hazard severity, and produce actionable recommendations that reduce worker injury rates and improve compliance documentation.
by kody-w
You can design experiments with appropriate controls, replicate structures, and sample sizes before conducting any bench work. This skill helps you establish clear endpoints, identify confounding variables, select the right statistical tests, and create reproducible data collection protocols—preventing costly failed experiments and increasing publishability.
by kody-w